摘要:
The present invention relates to a composition comprising essentially or consisting of: Vasoactive Intestinal Peptide (VIP), a sugar substitute, preferably sucralose, and tartaric acid, formulated as a powder or tablet for sublingual administration, wherein the VIP has not been chemically modified or conjugated, as well as to a method for manufacturing such a powder or tablet composition and use of the composition in the management of inflammatory diseases or conditions in a subject in need thereof by sublingual administration of the composition.
摘要:
The present invention relates to a freeze dried multiparticulate solid dosage form (1) that contains a plurality of microcapsules (2) having a core (2a) and a shell (2b) that are embedded in a freeze-dried, edible matrix (3). Microcapsules (2) contain an active ingredient which may be a pharmaceutical drug and/or a micronutrient. The solid dosage form may be a tablet, a wafer or even a crispy snack. A method for preparing such dosage forms is also disclosed.
摘要:
The present invention relates to an extended release pharmaceutical composition for oral administration comprising a therapeutically effective quantity of fesoterodine or a pharmaceutically acceptable salt, metabolite or derivative thereof, as an active ingredient, an effective quantity of ion exchange resin as a stabilizer in order to prevent the degradation and improve the physicochemical stability of the active ingredient in the finished dosage form and at least one pharmaceutically acceptable excipient as a rate controlling agent to modify/control the release of the active ingredient in the finished dosage form.
摘要:
The present invention relates to a pharmaceutical bilayer tablet comprising dabigatran etexilate free base or pharmaceutically acceptable salts of dabigatran etexilate and at least one pharmaceutically acceptable excipient.
摘要:
A dosage form comprising a tablet core and one or more discontinuous coated regions in various configurations on the surface of the dosage form is disclosed. A method for making the dosage form is also disclosed.
摘要:
The present disclosure relates to oral, abuse deterrent, edible soft chewable dosage forms for delivery of drugs that are susceptible to abuse to a human or animal subject. The dosage forms are provided as chewable tablets manufactured using a compression (tablet) press. The edible soft chew dosage forms can be administered to subjects that are unable to swallow conventional tablets or capsules whole. One or more abuse deterrent measures in the dosage forms prevent the conversion of the dosage form into a residue or extract suitable for non-oral administration, such as intranasal or intravenous abuse. The present disclosure also relates to processes of preparing the dosage form. Such soft chew dosage forms have hardness less than 2 kilopond, preferably less than 1 kilopond, more preferably no measurable hardness when measured with tablet hardness tester and friability less than 1%, preferably less than 0.5 %, more preferably less than 0.1% for 100 rotations (per USP); 200 rotations or 300 rotations.
摘要:
A process for producing a solid pharmaceutical oral dosage formulation comprising (i) hot melt extrusion of a mixture comprising: (a) at least one drug, (b) at least one polymer, (c) at least one lubricant, and (d) optionally at least one plasticizer; to provide a pharmaceutical filament, and (ii) fused-deposition modelling 3-dimensional printing from the said pharmaceutical filament.
摘要:
A product and process of manufacturing an edible soft-chewable dosage form for the delivery of pharmaceutically active ingredients or nutritional agents to an animal or human subject, by forming a granulated soft-chew mass by appropriate mixing and sifting steps, and forming tablets with a compression press. Such soft-chew dosage forms have hardness of less than about 2 kilopond and friability of less than about 1% at 300 rotations (per USP). The process for manufacturing such compressed soft-chew tablets employs compression (tablet) pressing equipment to produce soft-chew tablets of consistent weight and texture.
摘要:
In general, certain embodiments of the present disclosure provide compositions or mechanisms for oral administration of caffeine via a functional nutraceutical confectionary composition. According to various embodiments, a nutraceutical confectionary composition is provided with a ratio of caffeine to L-theanine ranging from about 1:1 to about 1:2. In some embodiments, the ratio of caffeine to L-theanine is about 2:3. In various embodiments, the nutraceutical confectionary composition may provide caffeine in a range from about 5 mg to about 100 mg per serving. L-theanine may be provided in a range from about 5 mg to about 200 mg per serving. In some embodiments, caffeine may comprise about 0.8% to 10% by weight of the composition; and L-theanine may comprise about 1.2% to 20% by weight of the composition. In certain embodiments, the nutraceutical confectionary composition may comprise a chewing gum.
摘要:
The present invention relates to solid oral pharmaceutical dosage forms that provide extended release of active ingredients and have abuse deterrent properties and the methods of making the same. More particularly, the present invention relates to solid oral extended release abuse deterrent dosage forms comprising at least one polycaprolactone (PCL) and at least one gelling agent.